Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Sep 27;207(10):2175–2186. doi: 10.1084/jem.20100637

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 Fourcade et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 3. — Ex vivo blockade of the Tim-3–Tim-3L pathway enhances cytokine production by NY-ESO-1–specific CD8⁺ T cells. (A and B) Representative dot plots from one melanoma patient (A) and summary data for all melanoma patients (n = 8; B) showing the percentages of A2/NY-ESO-1 157–165 tet⁺ CD8⁺ T cells that produce IFN-γ and TNF among total NY-ESO-1–specific CD8⁺ T cells after short ex vivo stimulation with cognate peptide in the presence of blocking anti–Tim-3 and/or anti–PD-L1 mAbs or an isotype control antibody (IgG). (C) Summary data for melanoma patients (n = 6) showing the percentages of A2/CMV 495–503 tet⁺ CD8⁺ T cells that produce IFN-γ and TNF among total CMV-specific CD8⁺ T cells after short ex vivo stimulation with cognate peptide in the presence of blocking anti–Tim-3 and/or anti–PD-L1 mAbs or an isotype control antibody (IgG). The p-values were calculated using the Wilcoxon signed rank test. Data shown are representative of two independent experiments performed in duplicate.